XML 67 R31.htm IDEA: XBRL DOCUMENT v3.22.4
Collaboration and license agreements (Tables)
 12 Months Ended
Dec. 31, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Allocation of total transaction price and unsatisfied transaction price
The following table summarizes the allocation of the total transaction price to the identified performance obligations under the arrangement, and the amount of the transaction price unsatisfied as of December 31, 2022 (in thousands):
Transaction
Price
Allocated
Transaction
Price
Unsatisfied
Performance obligations:
Research and development targets$61,074 $25,542 
Option rights6,748 2,502 
Total$67,822 $28,044 
Schedule of revenue from collaboration agreements
Revenue from collaboration agreements was as follows (in thousands):
Years Ended December 31,
20222021
Revenue from collaboration agreements:
Roche Agreement$4,939 $19,379 
Biogen Agreement19,214 15,720 
Calico Agreement6,943 10,686 
Total revenue from collaboration agreements$31,096 $45,785 
Schedule of financial information related to collaboration and license agreements
Supplemental information related to the collaboration and license agreements consisted of the following in the Company’s consolidated balance sheet as of December 31, 2022 (in thousands):
Accounts
Receivable
Deferred
Revenue,
Current
Deferred
Revenue,
Net of Current
Deferred
Revenue,
Total
Supplemental information:
Roche Agreement$417 $4,649 $16,895 $21,544 
Biogen Agreement— 11,427 — 11,427 
Calico Agreement1,056 542 — 542 
Total$1,473 $16,618 $16,895 $33,513 
Supplemental information related to the collaboration and license agreements consisted of the following in the Company’s consolidated balance sheet as of December 31, 2021 (in thousands):
Accounts
Receivable
Deferred
Revenue,
Current
Deferred
Revenue,
Net of Current
Deferred
Revenue,
Total
Supplemental information:
Roche Agreement$1,215 $5,601 $17,215 $22,816 
Biogen Agreement3,000 24,032 6,611 30,643 
Calico Agreement1,501 2,167 542 2,709 
Total$5,716 $31,800 $24,368 $56,168 
Schedule of supplemental financial information related to collaboration and license agreements
Supplemental financial information related to the collaboration and license agreements are (in thousands):
Years Ended December 31,
20222021
Revenue recognized that was included in the contract liability at the beginning of the period$25,412 $34,363 
Revenue recognized from performance obligations fully or partially satisfied in previous periods518 1,654